Faculty Information - TANAKA Norina

■ Published papers

1.	Original article	Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes. 2024/02/27
2.	Original article	The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma. 2023/02
3.	Original article	Very Early Increased Platelet Count within a Week after Initiation of High-Dose Dexamethasone Treatment Is Associated with Long-Term Response in Newly Diagnosed Immune Thrombocytopenia Patients. 2022/02
4.	Original article	High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage. 2021/10
5.	Case report	Successful Rituximab Treatment in Thrombotic Thrombocytopenic Purpura Patients Complicated by Other Autoimmune Disorders: Two Case Reports. 2021/09
6.	Original article	Correction to: Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities. 2020/11
7.	Original article	Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities. 2020/11
8.	Original article	Phase I study of cellular therapy using ex vivo expanded NK cell from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients. 2020/04
9.	Original article	SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma. 2020/04
10.	Original article	Herpes zoster after autologous haematopoietic stem cell transplantation without antiviral prophylaxis. 2019/09
11.	Original article	Clinical impact of serum soluble SLAMF7 in multiple myeloma. 2018/10
12.	Original article	L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma. 2013/11
13.	Review article	Job's syndrome 2013/03
14.	Original article	Treatment outcome of adult acute myeloid leukemia, A retrospective analysis in a single institution 2013/03
15.	Original article	Usefulness of the revised international prognostic index for diffuse large B-cell lymphoma patients treated with rituximab-based chemotherapy 2013/03
16.	Original article	Usefulness of (18)F-FDG PET/CT for detecting lesions in patients with POEMS syndrome 2012/12
17.	Original article	Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells 2011/09
18.	Original article	Level of DNA topoisomerase II alpha mRNA predicts the treatment response of relapsed acute leukemic patients 2009/07
Display 5 items
Display all(18)

■ Academic conference presentation

1.	Clinical course of immune thrombocytopenia after COVID-19 vaccination 2022/10/16
2.	Clinical features of MTX-associated lymphoproliferative disorders in rheumatoid arthritis patients 2022/10/16
3.	4 cases of COVID-19 infection in patients with hematological diseases 2021/09/23
4.	A case of primary mediastinal large B-cell lymphoma with pancreas involvement 2021/09/23
5.	Retrospective analysis of chronic myelomonocytic leukemia 2021/09/23
6.	Safety and efficacy of obinutuzumab-based chemoimmunotherapy for follicular lymphoma patients 2021/09/23
7.	Successful treatment with daratumumab in multiple myeloma patient with severe renal impairment 2021/09/23
8.	Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression 2019/12/09
9.	Clinical Features of Post-Transplant Lymphoproliferative Disease Are Different between Kidney-Transplant Recipients from a Cadaveric Donor and Those from a Living Donor 2019/12/08
10.	Ex-Vivo Expanded NK Cell Therapy Combined with Elotuzumab for MRD after Autologous Stem Cell Transplantation: A Phase I/ II Clinical Trial in Progress 2019/12/08
11.	Successful combined Treatment of blinatumomab and donor lymphocyte infusion after haploidentical hematopoietic cell transplantation in a relapsed Ph+ALL patient with BCR/ABL1 compound mutation 2019/08/30
12.	Clinical significance of KIR genotype in japanese patients with myelodysplastic syndrome 2019/06/15
13.	Non-Hodgkin lymphoma in patients with myeloproliferative neoplasms 2019/06/15
14.	The new immunoreceptor SLAMF3 promotes aggressive biological and clinical characteristics in multiple myeloma 2017/12/10
15.	Evaluation of staging and prognostic factors in multiple myeloma: KT-MM prognostic analysis 2017/10/22
16.	Long term efficacy of high dose dexamethasone for immune thrombocytopenia 2017/10/22
17.	Anti-CD20/anti-KIR antibody treatment enhances the cytotoxicity of NK cells against lymphoma cells 2017/10/21
18.	Clinical characteristics of CNS relapse in patients with diffuse large B-cell lymphoma 2017/10/20
19.	HSV and VZV disease during the first year after autologous hematopoietic stem cell transplantation 2017/10/20
20.	Retrospective analyse of methotrexate associated lymphoma 2017/10/20
21.	Autologous peripheral blood stem cell harvesting/ transplantation using modified Dexa-BEAM/BEAM regimens for the patients with high-risk lymphomas: a single center retrospective study. 2016/10/29
22.	Seven cases of non-Hodgkin B-cell lymphoma with heart involvement at diagnosis 2016/10/13
23.	Fractionated ICE with rituximab is safe and effective for relapse/refractory DLBCL patients with severe comorbidities 2015/12/06
24.	RELAL-88 exhibited high remission rates in refractory or relapsed adult precursor lymphoid neoplasms 2014/10/31
25.	Prognostic Implications Of PRAME Expression Levels In Myelodysplastic Syndromes. 2013/12/08
26.	Analysis of L265P mutation in the MYD88 gene in Waldenstrom's macroglobulinemia 2013/10/12
27.	A case of acute myeloid leukemia with t(11;19) (q23;p13.1) accompanied by severe DIC 2013/10/11
28.	Frequent mutation of the MYD88 gene in macroglobulinemia 2013/06/15
29.	siRNA silencing PRAME causes increased expression of TRAIL in K562 cell line 2011/10/14
30.	Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells 2010/12/04
31.	Expression of PRAME mRNA in acute leukemia cells at diagnosis and at relapse 2009/10/24
Display 5 items
Display all(31)

■ Qualifications & licenses

1.	2020/04	Board Certified Trainer of　the Japanese Society of Hematology
2.	2014/12	Fellow of the Japanese Society of Internal Medicine
3.	2013/04	General Clinical Oncologist (by JBCT)
4.	2012/06	Board Certified Trainer of　the Japanese Society of Internal Medicine
5.	2010/04	Board Certified Hematologist
6.	2007/10	Board Certified Member of the Japanese Society of Internal Medicine
Display 5 items
Display all(6)

■ Research areas

Hematology and medical oncology

■ Awards & honors

1.

2020/06

SHISEIKAI Scientific Award

■ Academic society memberships

1.

Japanese Cancer Association

■ Education

1.	1998/04～2004/03	Faculty of Medicine, Tokyo Women's Medical University, Graduated
2.	2006/04～2010/03	〔Doctoral course〕 hematology, Graduate School, Division of Medicine, Tokyo Women's Medical University, Completed, Doctor of Philosophy

■ Academic & professional experience

1.	2004/05～2006/03	NTT Medical Center Tokyo junior resident
2.	2006/04～2011/07	Tokyo Women's Medical University Department of Hematology
3.	2011/08～2021/05	Tokyo Women's Medical University Department of Hematology Assistant Professor
4.	2021/06～	Tokyo Women's Medical University Department of Hematology